Viropro Inc.
Viropro Inc.
Your view on VPRO
Overview
What the company does, where it operates, and who runs it.
About Viropro Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michelle Leanne Edythe Peake
- Headquarters
- 2151 O'Toole Avenue, San Jose, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michelle Leanne Edythe Peake
- Headquarters
- 2151 O'Toole Avenue, San Jose, CA, US
Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases.
The company is also involved in the transfer of its proprietary technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases, such as cancer, diabetes, hepatitis, or multiple sclerosis.
It manufactures biologics drugs, including bio-similars for pre-clinical, and Phase I, II, and III clinical trials; offers its clients with supply of mammalian cell proteins, such as monoclonal antibodies or recombinant proteins, or other cell-derived products; owns three clones that include two in insulin therapy and one for cancer therapy; and provides contractual research and manufacturing services to biotech and biopharmaceutical companies.
The company's contractual work activities include cloning, sequencing, purifying, developing, validating, and producing biopharmaceutical products and sub-products.
It has operations in Canada, the United Kingdom, and Malaysia. Viropro Inc. has collaboration agreement with Oncobiologics, Inc. to manufacture and commercialize monoclonal antibody products. The company is based in San Jose, California. Viropro Inc. is a subsidiary of Alpha Biologics Limited.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Viropro Inc., and the rating behind it. VPRO last traded at $0.0000; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Viropro Inc.. Starting points for Viropro Inc.: beta 3.31 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Viropro Inc.. Viropro Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Viropro Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Viropro Inc.. Viropro Inc. has reported as a listed company since 1995. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Viropro Inc. valued side by side against its closest peers. Viropro Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Viropro Inc., and how their positions are changing. At a $25,404 market value, institutional positions materially move Viropro Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Viropro Inc. executives and directors. Shares of Viropro Inc. have traded between $0.0000 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Viropro Inc.. Viropro Inc. is a $25,404 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Viropro Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Viropro Inc.. Coverage tracks Viropro Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.